Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
NS-229 by Nippon Shinyaku for Granulomatosis with Polyangiitis (Wegener's Granulomatosis): Likelihood of Approval
NS-229 is under clinical development by Nippon Shinyaku and currently in Phase II for Granulomatosis with Polyangiitis (Wegener's Granulomatosis). According...